Comparison of the immunomodulatory effects of the plant sterol β-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients

International Immunopharmacology

Volumn 9, Issue 1, 2009, Pages 153-157

  Desai, Forum ^a   Ramanathan, Murali ^a   Fink, Carol S ^a   Wilding, Gregory E ^a   Weinstock Guttman, Bianca ^a,b   Awad, Atif B ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b BUFFALO GENERAL HOSPITAL   (United States)

Author keywords

Sitosterol; Cytokines; Multiple sclerosis; Simvastatin

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 5; SIMVASTATIN; SITOSTEROL; STEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD CELL; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BLOOD CELLS; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-5; MIDDLE AGED; MULTIPLE SCLEROSIS; SIMVASTATIN; SITOSTEROLS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 58149465736     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.10.019     Document Type: Article

References (37)

1. Moghadasian M.H. Pharmacological properties of plant sterols in vivo and in vitro observations. Life Sci 67 6 (2000) 605-615
2. Ling W.H., and Jones P.J. Dietary phytosterols: a review of metabolism, benefits and side effects. Life Sci 57 3 (1995) 195-206
3. Chan Y.M., Varady K.A., Lin Y., Trautwein E., Mensink R.P., Plat J., et al. Plasma concentrations of plant sterols: physiology and relationship with coronary heart disease. Nutr Rev 64 9 (2006) 385-402
4. Awad A.B., and Fink C.S. Effect of beta-sitosterol on macrophage proinflammatory cytokines. FASEB J 19 (2005) 2797A
5. Awad A.B., Fink C.S., Williams H., and Kim U. In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells. Eur J Cancer Prev 10 6 (2001) 507-513
6. Awad A.B., Toczek J., and Fink C.S. Phytosterols decrease prostaglandin release in cultured P388D1/MAB macrophages. Prostaglandins Leukot Essent Fatty Acids 70 6 (2004) 511-520
7. Awad A.B., Roy R., and Fink C.S. Beta-sitosterol, a plant sterol, induces apoptosis and activates key caspases in MDA-MB-231 human breast cancer cells. Oncol Rep 10 2 (2003) 497-500
8. Awad A.B., Williams H., and Fink C.S. Phytosterols reduce in vitro metastatic ability of MDA-MB-231 human breast cancer cells. Nutr Cancer 40 2 (2001) 157-164
9. Awad A.B., Williams H., and Fink C.S. Effect of phytosterols on cholesterol metabolism and MAP kinase in MDA-MB-231 human breast cancer cells. J Nutr Biochem 14 2 (2003) 111-119
10. Awad A.B., and Fink C.S. Phytosterols as anticancer dietary components: evidence and mechanism of action. J Nutr 130 9 (2000) 2127-2130
11. Moreno J.J. Effect of olive oil minor components on oxidative stress and arachidonic acid mobilization and metabolism by macrophages RAW 264.7. Free Radic Biol Med 35 (2003) 1073-1081
12. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., and Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demylination. Annals Neurol 47 6 (2000) 707-717
13. Peterson J.W., Bo L., Mork S., Chang A., Ransohoff R.M., and Trapp B.D. VCAM-1-positive microglia target oligodendrocytes at the border of multiple sclerosis lesions. J Neuropathol Exp Neurol 61 6 (2002) 539-546
14. Trebst C., Sorensen T.L., Kivisakk P., Cathcart M.K., Hesselgesser J., and Horuk R. CCR1+/CCRS+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 159 5 (2001) 1701-1710
15. Neuhaus O., Archelos J.J., and Hartung H.P. Statins in multiple sclerosis: a new therapeutic option?. Mult Scler 9 5 (2003) 429-430
16. Neuhaus O., Stuve O., Archelos J.J., and Hartung H.P. Putative mechanisms of action of statins in multiple sclerosis - comparison to interferon beta and glatiramer acetate. J Neurol Sci 233 1-2 (2005) 173-177
17. Stuve O., Youssef S., Steinman L., and Zamvil S.S. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 16 3 (2003) 393-401
18. Neuhaus O., Stuve O., Zamvil S.S., and Hartung H.P. Are statins a treatment option for multiple sclerosis?. Lancet Neurol 3 6 (2004) 369-371
19. Neuhaus O., Strasser-Fuchs S., Fazekas F., Kieseier B.C., Niederwiesser G., Hartung H.P., et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59 7 (2002) 990-997
20. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler, Thromb Vasc Biol 18 11 (1998) 1671-1678
21. Thunyakitpisal P.D., and Chaisuparat R. Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci 94 4 (2004) 403-409
22. Birnbaum G., Altafullah I., and Reder A. A double blind, placebo controlled trial of atorvastatin in combination with subcutaneous interferon beta 1a in persons with multiple sclerosis. Neurology 68 Suppl 1 (2007) A206-A207
23. Dhawan N., and Reder A. Statins block interferon signaling in human immune cells: potential loss of the therapeutic effect of IFN-b in multiple sclerosis. Neurology 68 Suppl 1 (2007) A364
24. Rudick R., Pace A., Panzara M., et al. Effects of statins on IM interferon beta-1a, for RRMS. Multiple Sclerosis 13 Suppl 2 (2007) 204
25. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 1 (2001) 121-127
26. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 11 (1983) 1444-1452
27. Asadullah K., Sterry W., and Volk H.D. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 55 2 (2003) 241-269
28. Awad A.B., Chan K.C., Downie A.C., and Fink C.S. Peanuts as a source of beta-sitosterol, a sterol with anticancer properties. Nutr Cancer 36 2 (2000) 238-241
29. Katan M., Grundy S., Jones P., Law M., Miettinen T., and Paoletti R. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 78 (2003) 965-978
30. Bradford P., and Awad A.B. Phytosterols as anticancer compounds. Mol Nutr Food Res 51 (2007) 161-170
31. Awad A.B., von Holtz R.L., Cone J.P., Fink C.S., and Chen CY. Beta-sitosterol inhibits growth of HT-29 human colon cancer cells by activating the sphingomyelin cycle. Anticancer Res 18 1A (1998) 471-473
32. Nashed B., Yeganeh B., HayGlass K.T., and Moghadasian M.H. Antiatherogenic effects of dietary plant sterols are associated with inhibition of proinflammatory cytokine production in Apo E-KO mice. Journal of Nutrition 135 10 (2005) 2438-2444
33. Steinman L., Martin R., Bernard C., Conlon P., and Oksenberg J. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci 25 (2002) 491-505
34. Kang B.Y., Chung S.W., Chung W.J., Im S.Y., Hwang S.Y., and Kim T.S. Inhibition of interleukin-12 production in lipopolysaccharide-activated macrophages by curcumin. European Journal of Pharmacology 384 2-3 (1999) 191-195
35. Bright J.J., Musuro B.F., Du C., and Sriram S. Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis. J Neuroimmunol 82 1 (1998) 22-30
36. Windhagen A., Newcombe J., Dangond F., Strand C., Woodroofe M., Cuzner M., et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 182 (1995) 1985-1996
37. Imitola J., Chitnis T., and Khoury S.J. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 106 2 (2005) 163-177